Moderate to Severe Chronic Plaque Psoriasis
Also known as: Moderate-to-severe Chronic Plaque Psoriasis
Drug | Drug Name | Drug Description |
---|---|---|
DB00051 | Adalimumab | A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. |
DB00095 | Efalizumab | A monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB00051 | Adalimumab | Tumor necrosis factor | target |
DB00095 | Efalizumab | Integrin alpha-L | target |
DB00095 | Efalizumab | Integrin alpha-X | target |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB13906 | Aloe vera leaf | 1 / 2 | Active Not Recruiting | 1 |
DB01381 | Ginkgo biloba | 1 / 2 | Active Not Recruiting | 1 |
DB00065 | Infliximab | 1 / 2 | Active Not Recruiting | 1 |
DB14370 | Phellodendron amurense bark | 1 / 2 | Active Not Recruiting | 1 |
DB14565 | Sophora flavescens root | 1 / 2 | Active Not Recruiting | 1 |
DB15154 | Vunakizumab | 1 / 2 | Completed | 1 |
DB06410 | Doxercalciferol | 2 | Completed | 1 |
DB16698 | Neihulizumab | 2 | Completed | 2 |
DB00005 | Etanercept | 2 / 3 | Active Not Recruiting | 1 |
DB14004 | Tildrakizumab | 2 / 3 | Active Not Recruiting | 1 |
DB00051 | Adalimumab | 3 | Completed | 1 |
DB12917 | Bimekizumab | 3 | Active Not Recruiting | 1 |
DB12917 | Bimekizumab | 3 | Completed | 5 |
DB09029 | Secukinumab | 3 | Completed | 1 |
DB05679 | Ustekinumab | 3 | Completed | 3 |
DB00092 | Alefacept | 4 | Completed | 1 |